Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

INTERVIEW: Cigna VP says outcome-based contracts are here to stay

This article was originally published in Scrip

Executive Summary

While outcomes-based contracts between US health plans and pharmaceutical companies are the exception rather than the rule, that's changing, and Cigna was one of the first to test a model of reimbursing the cost of medicines based on the health value to the patient and the economic value to the payer versus paying for a drug simply because a doctor wrote a prescription for it.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC020990

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel